STC1 and breast cancer: Furthermore, STC1 may potentiate late breast cancer recurrence because the expression level of STC1 in primary breast tumours was strongly associated with late versus early recurrence at 6‐10 years following diagnosis among ER‐positive, tamoxifen‐treated patients (OR = 2.70, 95% CI: 1.22, 5.98).111